The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease
Abstract
Objective: Vedolizumab, a monoclonal antibody directed against the integrin heterodimer α4β7, is approved for the treatment of Crohn’s disease and ulcerative colitis. The efficacy of vedolizumab has been suggested to result from inhibition of intestinal T cell trafficking although human data to support this conclusion are scarce. We therefore performed a comprehensive analysis of vedolizumab-induced alterations in mucosal and systemic immunity in patients with inflammatory bowel disease (IBD), using anti-inflammatory therapy with the TNFα antibody infliximab as control. Design: Immunophenotyping, immunohistochemistry, T cell receptor profiling and RNA sequencing were performed using blood and colonic biopsies from patients with IBD before and during treatment with vedolizumab (n=18) or, as control, the anti-TNFα antibody infliximab (n=20). Leucocyte trafficking in vivo was assessed using single photon emission computed tomography and endomicroscopy. Results: Vedolizumab was not associated with alterations in the abundance or phenotype of lamina propria T cells and did not affect the mucosal T cell repertoire or leucocyte trafficking in vivo. Surprisingly, however, α4β7 antibody treatment was associated with substantial effects on innate immunity including changes in macrophage populations and pronounced alterations in the expression of molecules involved in microbial sensing, chemoattraction and regulation of the innate effector response. These effects were specific to vedolizumab, not observed in response to the TNFα antibody infliximab, and associated with inhibition of intestinal inflammation. Conclusion: Our findings suggest that modulation of innate immunity contributes to the therapeutic efficacy of vedolizumab in IBD. Trial registration number: NCT02694588
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms
Caporaso, J. G., Lauber, C. L., Walters, W. A., Berg-Lyons, D., Huntley, J., Fierer, N., Owens, S. M., Betley, J., Fraser, L., Bauer, M., et al. (2012) · The ISME Journal · doi:10.1038/ismej.2012.8 · Cited by 8,839
Counting absolute numbers of molecules using unique molecular identifiers
Kivioja, T., Vähärautio, A., Karlsson, K., Bonke, M., Enge, M., Linnarsson, S., & Taipale, J. (2012) · Nature Methods · doi:10.1038/nmeth.1778 · Cited by 1,010
O’Shea, N. R., Chew, T. S., Dunne, J., Marnane, R., Nedjat-Shokouhi, B., Smith, P. J., Bloom, S. L., Smith, A. M., & Segal, A. W. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw111 · Cited by 53
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Baumgart, D. C., & Le Berre, C. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1907607 · Cited by 354
Aden, K., Rehman, A., Waschina, S., Pan, W.-H., Walker, A., Lucio, M., Nunez, A. M., Bharti, R., Zimmerman, J., Bethge, J., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.07.025 · Cited by 263
Self-citationSchreiber, S., Aden, K., Bernardes, J. P., Conrad, C., Tran, F., Höper, H., Volk, V., Mishra, N., Blase, J. I., Nikolaus, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.02.062 · Cited by 259
Self-citation
Metadata
- Authors
- Zeissig, S., Rosati, E., Dowds, C. M., Aden, K., Bethge, J., Schulte, B., Pan, W. H., Mishra, N., Zuhayra, M., Marx, M., Paulsen, M., Strigli, A., Conrad, C., Schuldt, D., Sinha, A., Ebsen, H., Kornell, S.-C., Nikolaus, S., Arlt, A., Kabelitz, D., Ellrichmann, M., Lützen, U., Rosenstiel, P. C., Franke, A., & Schreiber, S.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2018-05-05
- Volume
- 68
- Issue
- 1
- Pages
- 25-39
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2801753207
- Cited by
- 203
- References
- 5
- FWCI
- 13.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. https://app.cochat.ai/papers/10.1136/gutjnl-2018-316023
- The paper
- Zeissig, S., Rosati, E., Dowds, C. M., Aden, K., Bethge, J., Schulte, B., Pan, W. H., Mishra, N., Zuhayra, M., Marx, M., Paulsen, M., Strigli, A., Conrad, C., Schuldt, D., Sinha, A., Ebsen, H., Kornell, S.-C., Nikolaus, S., Arlt, A., . . . Schreiber, S. (2019). Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut. https://doi.org/10.1136/gutjnl-2018-316023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.